CSR&D Research Career Development Transition Award Application

企业社会责任

• 批准号: 10059134
• 负责人: Gihyun Yoon
• 金额: --
• 依托单位: VA CONNECTICUT HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10059134
• 关键词: Alcohol consumption; Applications Grants; Area; Attention; Award; Biometry; Buprenorphine; Clinical; Clinical Research; Clinical Trials; Cognitive remediation; Communities; Data; Disease; Eszopiclone; Excitatory Amino Acid Antagonists; Funding; Goals; Growth and Development function; High Prevalence; Human; Injectable; Insulin; Intervention; K-Series Research Career Programs; Ketamine; Lead; Legal patent; Major Depressive Disorder; Mental Depression; Mental Health; Mental disorders; Mission; Morbidity - disease rate; N-Methylaspartate; Naltrexone; Neurosciences; Opioid Antagonist; Opioid Receptor; Paper; Patients; Pharmaceutical Preparations; Pharmacogenomics; Pharmacology; Pilot Projects; Policies; Post-Traumatic Stress Disorders; Protocols documentation; Psychiatrist; Publishing; Randomized; Research; Research Activity; Research Methodology; Research Peer Review; Research Personnel; Research Priority; Research Project Grants; Research Technics; Research Training; Risk; Sleeplessness; Substance abuse problem; Suicide; Suicide prevention; Targeted Research; Testing; Therapeutic; Time; Training Activity; Transition Career Development Award (K22); Translating; Translational Research; Trazodone; United States National Institutes of Health; Universities; Veterans; Wages; addiction; alcohol use disorder; antidepressant effect; base; clinical care; clinical development; clinical practice; cost; design; donepezil; double-blind placebo controlled trial; drug discovery; effective therapy; gabapentin; innovation; military veteran; mortality; neuroimaging; novel; novel strategies; opioid use disorder; pre-clinical research; preventive intervention

This application is for the Career Development Transition Award (CDTA). As a psychiatrist and clinical researcher, Dr. Yoon has designed and conducted several clinical trials and translational research driven by neuroscience-based hypotheses. The main goal of his research is to evaluate and develop medications for addictive and psychiatric disorders. He is a recipient of the VA Career Development Award (CDA-2) and the Merit Review Award. Dr. Yoon has tested novel approaches for the treatment of addictive and psychiatric disorders, particularly focusing on alcohol use disorder (AUD) and major depressive disorder (MDD). Many of his studies are the first to translate a novel observation in preclinical research to human therapy for these disorders. Addictive and psychiatric disorders produce enormous morbidity and mortality, and are very costly to the VA. The pharmacological approach he is testing has enormous potential to help patients suffering from addictive and psychiatric disorders. His current Merit Review award project is being conducted to evaluate whether the combination of ketamine (NMDA glutamate receptor antagonist) and naltrexone (opioid receptor antagonist) is effective in reducing depression and alcohol consumption. This study is highly innovative by asking important questions on (a) whether opioid receptor stimulation contributes to the antidepressant effects of ketamine and (b) whether the combination of naltrexone and ketamine might be a strategy to reduce addiction risk while rapidly treating depression. Since adequate treatment of MDD and AUD is of major clinical importance, the ketamine plus naltrexone approach may have a transformative impact on patients suffering from this condition. The CDTA will extend his capabilities beyond the current Merit Review Award project and lead his growth and development as a clinical researcher. His research plans during the CDTA period include: (a) conduct of six clinical trials that are currently funded (Project 1-6), (b) resubmission of two NIH R01 applications (Project 7-8), and (c) submission of two new grant applications (Project 9-10). Building on the findings from these projects, his long-term goal is to develop new and more effective pharmacological interventions for addictive and psychiatric disorders. In addition to these research activities, he will participate in training activities. Dr. Yoon is actively collaborating with VA and Yale researchers. They have collected data, shared research techniques, published papers, and submitted grant applications. There are three objectives. Aim #1: To conduct six clinical trials that are currently funded (Project 1-6). Aim #2: To resubmit two NIH R01 applications (Project 7-8) and submit two new grant applications (Project 9- 10) Aim #3: To participate in training activities in (1) ketamine and psychiatric research, (2) neuroscience and drug discovery, (3) addiction research, (4) clinical trials and research methodology, (5) neuroimaging, (6) pharmacogenomics, and (7) biostatistics. Conclusion: The CDTA will protect Dr. Yoon’s research training and activity to develop more effective treatments for addictive and psychiatric disorders.

职业发展过渡奖（CDTA）。作为一名精神病学家和临床 Yoon博士是一名研究员，他设计并进行了几项临床试验和转化研究， 基于神经科学的假设他的研究的主要目标是评估和开发药物， 成瘾和精神疾病。他是VA职业发展奖（CDA-2）和 优异评审奖。尹博士测试了治疗成瘾和精神疾病的新方法。 精神障碍，特别是酒精使用障碍（AUD）和重度抑郁症（MDD）。许多 他的研究是第一个将临床前研究中的新观察转化为人类治疗这些疾病的研究。 紊乱 成瘾性和精神障碍造成巨大的发病率和死亡率，并且治疗费用非常昂贵。 退伍军人事务部他正在测试的药理学方法具有巨大的潜力，可以帮助患有 成瘾和精神疾病。他目前的优秀评审奖项目正在进行评估， 氯胺酮（NMDA谷氨酸受体拮抗剂）和纳洛酮（阿片受体）的组合是否 拮抗剂）有效减少抑郁症和酒精消耗。这项研究具有很强的创新性， 提出关于（a）阿片受体刺激是否有助于抗抑郁作用的重要问题 和（B）纳洛酮和氯胺酮的组合是否可能是减少 成瘾风险，同时快速治疗抑郁症。由于充分治疗MDD和AUD是主要的临床问题， 重要的是，氯胺酮加纳洛酮的方法可能对患有 从这个条件。 CDTA将把他的能力扩展到目前的优秀评审奖项目之外， 作为临床研究人员的成长和发展。他在CDTA期间的研究计划包括： 进行目前资助的六项临床试验（项目1-6），（B）重新提交两项NIH R 01 （c）提交两份新的赠款申请（项目9-10）。基础上 从这些项目的发现，他的长期目标是开发新的和更有效的药理学 成瘾和精神疾病的干预措施。除了这些研究活动外，他还将参加 在培训活动中。Yoon博士积极与VA和耶鲁大学的研究人员合作。他们收集了数据， 分享研究技术，发表论文，提交资助申请。 有三个目标。 目标#1：进行目前资助的6项临床试验（项目1-6）。 目标#2：重新提交两份NIH R 01申请（项目7-8），并提交两份新的资助申请（项目9- 10）。 10）、 目标#3：参加（1）氯胺酮和精神病学研究，（2）神经科学和药物方面的培训活动 发现，（3）成瘾研究，（4）临床试验和研究方法，（5）神经成像，（6） 药物基因组学和（7）生物统计学。 结论：CDTA将保护Yoon博士的研究培训和活动，使其更有效地发展 治疗成瘾和精神疾病。